PMC8180869_01
Six pathological reports of TURBT. (A) 2016-07-07, Papillary urothelial carcinoma, low-grade; (B) 2016-09-27, Necrotic tissue; (C) 2017-06-15, Chronic inflammation of the bladder mucosa with atypical hyperlasia; (D) 2017-12-14, Chronic inflammation of the bladder mucosa with atypical hyperlasia; (E) 2018-05-10, Papillary urothelial carcinoma, low-grade; (F) 2018-11-23, Papillary urothelial carcinoma, high-grade.
fonc-11-643413-g001.jpg
PMC8180869_01_fonc-11-643413-g001.jpg
f1
TURBT pathology indicated that the patient has stage-TaG1 UBC ( Figure 1A ). Between July 2016 and May 2018, TURBT was repeated five times due to cancer recurrence and progression ( Figures 1B-F ).
Imaging manifestations of treatment.
fonc-11-643413-g002.jpg
PMC8180869_01_fonc-11-643413-g002.jpg
f2
Unfortunately, after four cycles treatment, the patient's abdominal CT ( Figure 2 -6) showed that the treatment had failed and the patients' condition continued to deteriorate. CT ( Figure 2 ) and PR was observed. Currently, the cancer has been stable for over 11 months and the patient is still being followed up.
The molecular characterization.
fonc-11-643413-g003.jpg
PMC8180869_01_fonc-11-643413-g003.jpg
f3
Unfortunately, after four cycles treatment, the patient's abdominal CT ( Figure 2 -6) showed that the treatment had failed and the patients' condition continued to deteriorate. To provide further treatment to this patient, we performed genetic sequencing and molecular characterization confirmed the presence of FGFR3, PIK3CA, and TP53 mutations in the patient ( Figure 3 ).
The timeline of treatment.
fonc-11-643413-g004.jpg
PMC8180869_01_fonc-11-643413-g004.jpg
f4
Unfortunately, after four cycles treatment, the patient's abdominal CT ( Figure 2 -6) showed that the treatment had failed and the patients' condition continued to deteriorate. The timeline of the patients' treatment is described in  Figure 4 .